Celgene’s investigational and second-generation CAR T-cell therapy bb2121 is showing real promise in treating advanced multiple myeloma patients, those with…
Articles by Janet Stewart, MSc
Screening people with a family history of a multiple myeloma precursor would significantly reduce the chance that a person would develop and…
The European Commission has extended Xgeva‘s (denosumab) approval for the prevention of bone lesions in multiple myeloma patients,…
The combination of Revlimid (lenalidomide) and dexamethasone for the treatment of relapsed or refractory multiple myeloma showed similar benefits in routine…
Scientists have developed a new test that shortens the time it takes to assess the success of bone marrow transplants…
Janssen Pharmaceuticals has requested the U.S. Food and Drug Administration (FDA) add a new indication for Darzalex (daratumumab)…
Patients with relapsed and refractory multiple myeloma lived roughly 3.6 months longer without their disease worsening when they received…
Adding Venclexta (venetoclax) to Velcade (bortezomib) and dexamethasone has shown promising effectiveness and an acceptable safety profile in multiple myeloma…
Multiple myeloma patients older than 65 years benefit as much as younger patients from autologous stem cell transplant (ASCT), according…